Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Original) A purified mammalian RapR6 protein.

2. (Original) The protein of claim 1 which comprises the amino acid sequence substantially as set forth in SEQ ID NO:3 or **11.**

3. (Original) A purified protein encoded by a nucleic acid capable of hybridizing to a DNA having a sequence consisting of the coding region of SEQ IDNO:2 or 10.

4. (Original) A purified derivative or analog of the protein of claim 1, which displays one or more functional activities of a mammalian RapR6 protein.

5. (Original) The derivative or analog of claim 4 which is capable of binding to an antibody directed against a mammalian RapR6 protein.

6. (Original) A purified fragment of a mammalian RapR6 protein.

7. (Original) The fragment of claim 6, wherein said fragment comprises a WD40 domain of a mammalian RapR6 protein.

8. (Original) The fragment of claim 7, wherein said mammalian RapR6 protein is a human RapR6 protein, and wherein said fragment comprises amino acids 24-63 of said RapR6 protein.

9. (Original) The fragment of claim 7, wherein said mammalian RapR6 protein is a human RapR6 protein, and wherein said fragment comprises amino acids 66-105 of said RapR6 protein.

10. (Original) The fragment of claim 7, wherein said mammalian RapR6 protein is a human RapR6 protein, and wherein said fragment comprises amino acids 108-154 of said RapR6 protein.

11. (Original) The fragment of claim 7, wherein said mammalian RapR6 protein is a human RapR6 protein, and wherein said fragment comprises amino acids 203-244 of said RapR6 protein.

12. (Original) The fragment of claim 7, wherein said mammalian RapR6 protein is a human RapR6 protein, and wherein said fragment comprises amino acids 247-287 of said RapR6 protein.

13. (Original) The fragment of claim 6, wherein said fragment comprises a transmembrane domain of a mammalian RapR6 protein.

14. (Original) The fragment of claim 13, wherein said mammalian RapR6 protein is a human RapR6 protein, and wherein said fragment comprises amino acids 1-21 of said RapR6 protein.

15. (Original) The fragment of claim 13, wherein said mammalian RapR6 protein is a human RapR6 protein, and wherein said fragment comprises amino acids 210-232 of said RapR6 protein.

16. (Original) The fragment of claim 6, wherein said fragment does not comprise a WD40 domain or a transmembrane domain of a mammalian RapR6 protein.

17. (Original) The fragment of claim 16, wherein said mammalian RapR6 protein is a human RapR6 protein, and wherein said fragment comprises amino acids 155-202 of said RapR6 protein.

18. (Currently Amended) A molecule comprising the fragment of ~~any one of claims 6-17~~ claim 6.

19. (Original) A protein comprising an amino acid sequence that has at least 60% identity to a domain of a mammalian RapR6 protein, in which the percentage identity is determined over an amino acid sequence of identical size to the domain.

20. (Original) A protein comprising an amino acid sequence that has at least 90% identity to a domain of a mammalian RapR6 protein, in which the percentage identity is determined over an amino acid sequence of identical size to the domain.

21. (Original) A polypeptide comprising a fragment of a mammalian RapR6 protein consisting of at least 6 amino acids fused via a covalent bond to an amino acid sequence of a second peptide, wherein said second peptide is not comprised in a mammalian RapR6 protein.

22. (Original) The polypeptide of claim 21, wherein the fragment of the mammalian RapR6 protein is a fragment capable of binding to an anti-RapR6 protein antibody.

23. (Original) The polypeptide of claim 22, wherein the fragment capable of binding to an anti-RapR6 protein antibody further lacks one or more domains of the RapR6 protein.

24. (Original) An antibody which is capable of binding to a mammalian RapR6 protein.

25. (Original) The antibody of claim 24 which is a monoclonal antibody.

26. (Currently Amended) A molecule comprising a fragment of the antibody of claim ~~26~~ 24, wherein said fragment is capable of binding to a RapR6 protein.

27. (Original) An isolated nucleic acid comprising a nucleotide sequence encoding a mammalian RapR6 protein as set forth in SEQ ID NO:2 or 10.

28. (Original) The nucleic acid of claim 27 which is DNA.

29. (Original) An isolated nucleic acid comprising a nucleotide sequence complementary to the nucleotide sequence of claim 27.

30. (Original) An isolated nucleic acid hybridizable to the nucleic acid of claim 29.

31. (Original) An isolated nucleic acid comprising a fragment of a mammalian RapR6 gene consisting of at least 8 nucleotides.

32. (Original) An isolated nucleic acid comprising a fragment of a mammalian RapR6 gene comprising anyone of exons 1-6 of a mammalian RapR6 gene.

33. (Original) An isolated nucleic acid comprising a fragment of a mammalian RapR6 gene comprising an intron, or a fragment thereof, of a mammalian RapR6 gene.

34. (Original) An isolated nucleic acid comprising a nucleotide sequence encoding a fragment of a mammalian RapR6 protein that displays one or more functional activities of the mammalian RapR6 protein.

35. (Currently Amended) An isolated nucleic acid comprising a nucleotide sequence encoding ~~anyone of the fragments of claims 6-17~~ the fragment of claim 6.

36. (Original) A recombinant cell containing the nucleic acid of claim 35.

37. (Original) A method of producing a mammalian RapR6 protein comprising:

(a) growing a recombinant cell containing the nucleic acid of claim 36 such that the encoded fragment of said mammalian RapR6 protein is expressed by the cell; and

(b) recovering said expressed fragment of said mammalian RapR6 protein.

38. (Original) The product of the process of claim 37.

39. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a mammalian RapR6 protein and a pharmaceutically acceptable carrier.

40. (Original) A pharmaceutical composition comprising a therapeutically effective amount of an antibody capable of binding to a mammalian RapR6 protein and a pharmaceutically acceptable carrier.

41. (Original) A method for generating a genetically modified cell having altered sensitivity to rapamycin, said method comprising introducing into the genome of a cell of a selected cell type of an organism a knockout DNA construct, said knockout DNA construct comprising (i) a regulated promoter and (ii) a selection marker coding sequence under the control of said regulated promoter, wherein said regulated promoter, when activated, initiates RNA transcription to produce an RNA; wherein, when said regulated promoter is activated, said genetically modified cell is rapamycin resistant if cells of said selected cell type is rapamycin sensitive or is rapamycin sensitive if cells of said selected cell type is rapamycin resistant.

42. (Original) The method of claim 41, wherein said knockout DNA construct further comprises a rapid cloning element comprising a replication origin sequence comprising sequences for initiation of replication and segregation and a bacterial selection marker.

43. (Original) The method of claim 42, wherein said replication origin sequence is an Ori and said bacterial selection marker is a chloramphenicol resistance gene.

44. (Original) The method of claim 41, wherein said method further comprising activating said regulated promoter and identifying said genetically modified cell by a method comprising identifying a change in rapamycin resistance in said genetically modified cell.

45. (Original) The method of claim 42, further comprising cloning a fragment of genomic sequence by a method comprising: (a) obtaining a nucleotide sequence comprising said rapid cloning element and said fragment of genomic sequence; (b) circularizing said nucleotide sequence to generate a circular plasmid; and (c) transforming a suitable host cell using said circular plasmid.

46. (Original) The method of claim 44, further comprising determining the sequence of said fragment of genomic sequence by a method comprising sequencing said circular plasmid.

47. (Original) The method claim 45, further comprising determining the location of said fragment of genomic sequence in said genome of said cell by a method comprising comparing said sequences with the genomic sequence of said selected cell type.

48. (Original) The method of claim 41, wherein said method further comprising, prior to said step of introducing said knockout DNA construct, introducing into the genome of cells of said selected cell type a DNA construct encoding a transactivator, said DNA construct comprising (i) a promoter and (ii) a nucleotide sequence encoding a transactivator, said nucleotide sequence being under the control of said promoter, wherein said regulated promoter is activated by said transactivator, and wherein said genetically modified cell is generated by introducing said knockout DNA construct into a cell comprising said DNA construct encoding said transactivator.

49. (Original) The method of claim 48, wherein said regulated promoter is a tetracycline regulated promoter, and wherein said transactivator activates said regulated promoter in the absence of tetracycline.

50. (Original) The method of claim 49, wherein said knockout DNA construct further comprises a rapid cloning element comprising a replication origin sequence comprising sequences for initiation of replication and segregation and a bacterial selection marker.

51. (Original) The method of claim 50, wherein said replication origin sequence is an Ori and said bacterial selection marker is a chloramphenicol resistance gene.

52. (Original) The method of claim 51, wherein said method further comprising identifying said genetically modified cell by a method comprising identifying a change in rapamycin resistance in said genetically modified cell.

53. (Original) The method of claim 51, further comprising cloning a fragment of genomic sequence by a method comprising: (a) obtaining a nucleotide sequence comprising said rapid cloning element and said fragment of genomic sequence; (b) circularizing said nucleotide sequence to generate a circular plasmid; and (c) transforming a suitable host cell using said circular plasmid.

54. (Original) The method of claim 53, further comprising determining the sequence of said fragment of genomic sequence by a method comprising sequencing said circular plasmid.

55. (Original) The method of claim 54, further comprising determining the location of said fragment of genomic sequence in said genome of said cell by a method comprising comparing said sequences with the genomic sequence of said selected cell type.

56. (Currently Amended) The method of ~~anyone of claims 41-55~~ claim 41, wherein said selected cell type is a rapamycin sensitive cell type.

57. (Original) The method of claim 56, wherein said organism is a human.

58. (Original) The method of claim 56, wherein said organism is a mouse.

59. (Original) The method of claim 58, wherein said selected cell type is the murine neuroblastoma N2a cell line.

60. (Original) The method of claim 56, wherein said knockout DNA construct is integrated at a location in a RapR6 gene.

61. (Currently Amended) The method of ~~anyone of claims 41-55~~ claim 41, wherein said selected cell type is a rapamycin resistant cell type.

62. (Original) The method of claim 61, wherein said organism is a human.

63. (Original) The method of claim 61, wherein said organism is a mouse.

64. (Original) A method for treating a mammal having a cancer, said cancer being caused by defective regulation of a RapR6 gene and/or defective activity of a protein encoded by said RapR6 gene, said method comprising administering to said mammal a therapeutically sufficient amount of an agent, said agent regulating the expression of said RapR6 gene and/or activity of said protein encoded by said RapR6 gene.

65. (Original) The method of claim 64, wherein said cancer is caused by a mutation in said RapR6 gene, and wherein said agent causes the expression of a normal version of said RapR6 gene in cells of said cancer.

66. (Original) The method of claim 64, wherein said agent comprises a RapR6 protein or a therapeutically equivalent fragment thereof.

67. (Original) A method for treating a mammal having a cancer, comprising administering to said mammal a therapeutically sufficient amount of an agent, said agent regulating the expression of a RapR6 gene and/or activity of a protein encoded by said RapR6 gene such that rapamycin resistance is regulated, wherein said mammal is subject to a therapy comprising administrating to said mammal a therapeutically sufficient amount of rapamycin or an analog or derivative of rapamycin.

68. (Original) A method for treating a mammal having a cancer, comprising administering to said mammal i) a therapeutically sufficient amount of an agent, said agent regulating the expression of a RapR6 gene and/or activity of a protein encoded by said RapR6 gene such that rapamycin resistance is regulated, and ii) a therapeutically sufficient amount of rapamycin or an analog or derivative of rapamycin.

69. (Currently Amended) The method of claim 67 ~~or 68~~, wherein said agent causes the expression of a normal version of said RapR6 gene in cells of said cancer.

70. (Currently Amended) The method of claim 67 ~~or 68~~, wherein said agent comprises a RapR6 protein or a therapeutically equivalent fragment thereof.

71. (Original) A method for diagnosing a cancer or a predisposition to said cancer in a mammal, said cancer being a result of defective regulation of a RapR6 gene, said method comprising determining an expression level of said RapR6 gene in cells of said mammal, wherein said expression level deviated from a predetermined threshold level indicates that said mammal has or is predisposed of said cancer.

72. (Original) The method of claim 71, wherein said expression level of said RapR6 gene is determined by a method comprising measuring the expression level of said RapR6 gene using one or more polynucleotide probes, each of said one or more polynucleotide probes comprising a nucleotide sequence in said RapR6 gene.

73. (Original) The method of claim 72, wherein said one or more polynucleotide probes comprise at least one polynucleotide probe comprising a nucleotide sequence within one of exons 1-6 of said RapR6 gene.

74. (Original) The method of claim 72, wherein said one or more polynucleotide probes comprise at least one polynucleotide probe comprising a nucleotide sequence of said RapR6 gene which does not encode a WD40 domain of the encoded RapR6 protein.

75. (Original) The method of claim 72, wherein said one or more polynucleotide probes comprise at least one polynucleotide probe comprising a nucleotide sequence within an intron of said RapR6 gene.

76. (Original) The method of claim 72, wherein said one or more polynucleotide probes comprise at least one polynucleotide probe comprising a nucleotide sequence comprised in the nucleotide sequence encoding a WD40 domain in the encoded RapR6 protein.

77. (Original) The method of claim 72, wherein said one or more polynucleotide probes comprise at least one polynucleotide probe comprising a nucleotide sequence comprised in the nucleotide sequence encoding a transmembrane domain in the encoded RapR6 protein.

78. (Currently Amended) The method of ~~anyone of claim 71-76~~ claim 71, wherein said one or more polynucleotide probes are polynucleotide probes on a microarray.

79. (Original) A method for diagnosing a cancer or a predisposition to said cancer in a mammal, said cancer being a result of defective regulation of a RapR6 gene, said method comprising determining a level of abundance of a protein encoded by said RapR6 gene in cells of said mammal, wherein said level of abundance of said protein deviated from a predetermined threshold level indicates that said mammal has or is predisposed of said cancer.

80. (Original) A method for diagnosing a cancer or a predisposition to said cancer in a mammal, said cancer being a result of defective regulation of a RapR6 gene, said method

comprising determining a level of activity of a protein encoded by said RapR6 gene in cells of said mammal, wherein said activity level deviated from a predetermined threshold level indicates that said mammal has or is predisposed of said cancer.

81. (Currently Amended) The method of claim 79 ~~or 80~~, wherein said mammal is a human.

82. (Original) The method of claim 81, wherein said protein is a human RapR6 protein as depicted in SEQ ID NO: 11.

83. (Currently Amended) The method of claim ~~83 or 84~~ 81, wherein said mammal is a mouse.

84. (Original) The method of claim 83, wherein said protein is murine RapR6 protein as depicted in SEQ ID NO:3.

85. (Original) A method for evaluating rapamycin resistance in a cell, said method comprising determining an expression level of a RapR6 gene in said cell, wherein said expression level deviated from a predetermined threshold level indicates that said cell is rapamycin resistant.

86. (Original) The method of claim 85, wherein said expression level of said RapR6 gene is determined by a method comprising measuring the expression level of

said RapR6 gene using one or more polynucleotide probes, each of said one or more polynucleotide probes comprising a nucleotide sequence in said RapR6 gene.

87. (Original) The method of claim 86, wherein said one or more polynucleotide probes comprise at least one polynucleotide probe comprising a nucleotide sequence within one of exons 1-6 of said RapR6 gene.

88. (Original) The method of claim 87, wherein said one or more polynucleotide probes comprise at least one polynucleotide probe comprising a nucleotide sequence of said RapR6 gene which does not encode a WD40 domain of the encoded RapR6 protein.

89. (Original) The method of claim 87, wherein said one or more polynucleotide probes comprise at least one polynucleotide probe comprising a nucleotide sequence of said RapR6 gene which does not encode a transmembrane domain of the encoded RapR6 protein.

90. (Original) The method of claim 80, wherein said one or more polynucleotide probes comprise at least one polynucleotide probe comprising a nucleotide sequence within an intron of said RapR6 gene.

91. (Currently Amended) The method of ~~anyone of claims 79-90~~ 79, wherein said one or more polynucleotide probes are polynucleotide probes on a micro array.

92. (Original) The method of claim 91, wherein said one or more polynucleotide probes comprise at least one polynucleotide probe comprising a nucleotide sequence comprised in the nucleotide sequence encoding a WD40 domain in a RapR6 protein.

93. (Original) The method of claim 91, wherein said one or more polynucleotide probes comprise at least one polynucleotide probe comprising a nucleotide sequence comprised in the nucleotide sequence encoding a transmembrane domain in a RapR6 protein.

94. (Original) A method for evaluating rapamycin resistance in a cell, said method comprising determining a level of abundance of a protein encoded by a RapR6 gene in said cell, wherein said level of abundance of said protein deviated from a predetermined threshold level indicates that said cell is rapamycin resistant.

95. (Original) A method for evaluating rapamycin resistance in a cell, said method comprising determining a level of activity of a protein encoded by a RapR6 gene in said cell, wherein said activity level deviated from a predetermined threshold level indicates that said cell is rapamycin resistant.

96. (Currently Amended) The method of claim 94 ~~or 95~~, wherein said cell is a human cell.

97. (Original) The method of claim 96, wherein said protein is a human RapR6 protein as depicted in SEQ ID NO:11.

98. (Currently Amended) The method of ~~claims 94 or 95~~ claim 94, wherein said cell is a murine cell.

99. (Original) The method of claim 98, wherein said protein is murine RapR6 protein as depicted in SEQ ID NO:3.

100. (Original) A method for regulating rapamycin resistance in a cell, comprising contacting said cell with a sufficient amount of an agent such that rapamycin resistance is regulated, said agent regulating the expression of a RapR6 gene and/or the activity of a protein encoded by said RapR6 gene.

101. (Original) A method for regulating rapamycin resistance in a mammal, comprising administering to said mammal a therapeutically sufficient amount of an agent such that rapamycin resistance is regulated, said agent regulating the expression of a RapR6 gene and/or the activity of a protein encoded by said RapR6 gene.

102. (Original) A method for regulating growth of a cell, comprising contacting said cell with i) a sufficient amount of an agent such that rapamycin resistance is regulated, said agent regulating the expression of a RapR6 gene and/or the activity of a

protein encoded by said RapR6 gene; and ii) a sufficient amount of rapamycin or an analog or derivative of rapamycin.

103. (Currently Amended) The method of ~~claims 100, 101 or 102~~ claim 100, wherein said agent causes the expression of a normal version of said RapR6 gene in said cell.

104. (Currently Amended) The method of ~~claims 100, 101 or 102~~ claim 100, wherein said agent comprises a RapR6 protein or a therapeutically equivalent fragment thereof.

105. (Original) A method of identifying an agent that is capable of regulating rapamycin resistance, wherein said agent is capable of modulating the expression of a RapR6 gene and/or the activity of a protein encoded by said RapR6 gene, said method comprising comparing inhibitory effect of rapamycin on cells expressing said RapR6 gene in the presence of said agent with inhibitory effect of rapamycin on cells expressing said RapR6 gene in the absence of said agent, wherein a difference in said inhibitory effect of rapamycin identifies said agent as capable of regulating rapamycin resistance.

106. (Original) A method of identifying an agent that is capable of regulating rapamycin resistance, wherein said agent is capable of modulating the expression of a RapR6 gene and/or activity of a protein encoded by said RapR6 gene, said method comprising:

(a) contacting a first cell expressing said RapR6 gene with rapamycin in the presence of said agent and measuring a first growth inhibitory effect;

(b) contacting a second cell expressing said RapR6 gene with rapamycin in the absence of said agent and measuring a second growth inhibitory effect; and

(c) comparing said first and second inhibitory effects measured in said step (a) and (b),

wherein a difference between said first and second inhibitory effects identifies said agent as capable of regulating rapamycin resistance.

107. (Currently Amended) The method of ~~claims 105 or 106~~ claim 105, wherein said agent comprises a RapR6 protein or a functionally equivalent fragment thereof.

108. (Currently Amended) The method of ~~claims 105 or 106~~ claim 105, wherein said agent causes the expression of a normal version of said RapR6 gene in a cell.

109. (Original) A method of producing an antibody that binds specifically to a RapR6 protein, comprising raising said antibody against said RapR6 protein or a polypeptide comprising an fragment of said RapR6 protein.

110. (Original) The method of claim 109, wherein said RapR6 protein is a human RapR6 protein.

111. (Original) The method of claim 109, wherein said RapR6 protein is a murine RapR6 protein.

112. (Original) An antibody that binds specifically to a RapR6 protein or a fragment of said RapR6 protein such that binding of said antibody to said RapR6 protein regulates rapamycin resistance.

113. (Original) The antibody of claim 112, wherein said RapR6 protein is a human RapR6 protein.

114. (Original) The antibody of claim 112, wherein said RapR6 protein is a murine RapR6 protein.

115. (Original) An agent that regulates the expression of a RapR6 gene such that rapamycin resistance is regulated.

116. (Original) The agent of claim 115, wherein said agent comprises a molecule which regulates expression of said RapR6 gene.

117. (Original) The agent of claim 115, wherein said agent causes the expression of a normal version of said RapR6 gene in a cell.

118. (Original) A cell comprising a knockout DNA construct at a RapR6 locus, said knockout DNA construct comprising (i) a regulated promoter and (ii) a selection marker coding sequence under the control of said regulated promoter, wherein said regulated promoter, when activated, initiates RNA transcription to produce an RNA.

119. (Original) The cell of claim 118, wherein said knockout DNA construct is inserted in the intron between exon 1 and exon 2 to produce a truncated fragment of the protein encoded by the sequence at said RapR6 locus.

120. (Original) The cell of claim 118, further comprising a DNA construct encoding a transactivator, said DNA construct comprising (i) a promoter and (ii) a nucleotide sequence encoding said transactivator, said nucleotide sequence being under the control of said promoter, wherein said transactivator activates said regulated promoter.

121. (Original) The cell of claim 118, wherein said knockout DNA construct further comprises a rapid cloning element comprising a replication origin sequence comprising sequences for initiation of replication and segregation and a bacterial selection marker.

122. (Original) The cell of claim 121, wherein said replication origin sequence is an Ori and said bacterial selection marker is a chloramphenicol resistance gene.

123. (Original) The cell of claim 122, wherein said regulated promoter is a tetracycline regulated promoter, and wherein said transactivator activates said regulated promoter in the absence of tetracycline.

124. (Currently Amended) The cell of ~~any one of claims 118-123~~ claim 118, wherein said cell is a rapamycin sensitive cell.

125. (Original) The cell of claim 124, wherein said cell is a human cell.

126. (Original) The cell of claim 124, wherein said cell is a murine cell.

127. (Original) The cell of claim 126, wherein said cell is a murine neuroblastoma N2a cell.

128. (Original) The cell of claim 127, wherein said integration site is in the intron between exon 1 and exon 2 of said RapR6 locus.

129. (Currently Amended) The cell of ~~any one of claims 118-123~~ claim 118, wherein said cell is a rapamycin resistant cell.

130. (Original) A microarray for diagnosing rapamycin resistance, said micro array comprising one or more polynucleotide probes, wherein each said polynucleotide probe comprises a nucleotide sequence in a RapR6 gene.

131. (Original) The microarray of claim 130, wherein said one or more polynucleotide probes comprise at least one polynucleotide probe comprising a nucleotide sequence within one of exons 1-6 of said RapR6 gene.

132. (Original) The microarray of claim 130, wherein said one or more polynucleotide probes comprise at least one polynucleotide probe comprising a nucleotide sequence within an intron of said RapR6 gene.

133. (Original) A kit for diagnosis of rapamycin resistance, comprising in one or more containers one or more polynucleotide probes, wherein each said polynucleotide probe comprises a nucleotide sequence in a RapR6 gene.

134. (Original) A kit for screening for agents which regulate rapamycin resistance and/or tumorgenesis, comprising in one or more containers (i) the cell of claim 118; (ii) tetracycline or a derivative or analog thereof; and (iii) rapamycin or a derivative or analog thereof.

135. (New) The method of claim 68, wherein said agent causes the expression of a normal version of said RapR6 gene in cells of said cancer.

136. (New) The method of claim 68, wherein said agent comprises a RapR6 protein or a therapeutically equivalent fragment thereof.

137. (New) The method of claim 80, wherein said mammal is a human.

138. (New) The method of claim 137, wherein said protein is a human RapR6 protein as depicted in SEQ ID NO:11.

139. (New) The method of claim 80, wherein said mammal is a mouse.

140. (New) The method of claim 139, wherein said protein is murine RapR6 protein as depicted in SEQ ID NO:3.

141. (New) The method of claim 95, wherein said cell is a human cell.

142. (New) The method of claim 141, wherein said protein is a human RapR6 protein as depicted in SEQ ID NO:11.

143. (New) The method of claim 95, wherein said cell is a murine cell.

144. (New) The method of claim 143, wherein said protein is murine RapR6 protein as depicted in SEQ ID NO:3.

145. (New) The method of claim 101, wherein said agent causes the expression of a normal version of said RapR6 gene in said cell.

146. (New) The method of claim 102, wherein said agent causes the expression of a normal version of said RapR6 gene in said cell.

147. (New) The method of claim 101, wherein said agent comprises a RapR6 protein or a therapeutically equivalent fragment thereof.

148. (New) The method of claim 102, wherein said agent comprises a RapR6 protein or a therapeutically equivalent fragment thereof.

149. (New) The method of claim 106, wherein said agent comprises a RapR6 protein or a functionally equivalent fragment thereof.

150. (New) The method of claim 106, wherein said agent causes the expression of a normal version of said RapR6 gene in a cell.

151. (New) The method of claim 80, wherein said one or more polynucleotide probes are polynucleotide probes on a micro array.

152. (New) The method of claim 151, wherein said one or more polynucleotide probes comprise at least one polynucleotide probe comprising a nucleotide sequence comprised in the nucleotide sequence encoding a WD40 domain in a RapR6 protein.

153. (New) The method of claim 151, wherein said one or more polynucleotide probes comprise at least one polynucleotide probe comprising a nucleotide sequence comprised in the nucleotide sequence encoding a transmembrane domain in a RapR6 protein.

154. (New) The method of claim 85, wherein said one or more polynucleotide probes are polynucleotide probes on a micro array.

155. (New) The method of claim 154, wherein said one or more polynucleotide probes comprise at least one polynucleotide probe comprising a nucleotide sequence comprised in the nucleotide sequence encoding a WD40 domain in a RapR6 protein.

156. (New) The method of claim 154, wherein said one or more polynucleotide probes comprise at least one polynucleotide probe comprising a nucleotide sequence comprised in the nucleotide sequence encoding a transmembrane domain in a RapR6 protein.